Related Experiment Videos
Turning p53 on or off: either way may treat cancer
1Division of Pediatric Hematology/Oncology, Dana Farber Cancer Institute and Children's Hospital, Harvard Medical School, MA, USA
Abstract:
The p53 tumor suppressor gene is likely the most commonly mutated tumor suppressor gene in human cancer. Its functions include modulation of both cell cycle arrest and apoptosis. Animal models and human clinical data suggest that in some settings, p53 may be prognostically significant, reflecting its role as a key regulator of cell death during cancer therapy. Two recent strategies have been proposed to exploit p53's unique death-regulating activity in opposite directions and improve cancer treatment. One approach seeks to inhibit p53 in normal cells thereby diminishing therapy-related, p53-dependent toxicity. The other utilizes a peptide derived from the C-terminus of p53 to activate wild-type or mutant p53 proteins, triggering apoptosis with selectivity for transformed cells. These novel approaches hold promise for targeting p53 in cancer therapy and may shed light on mechanisms underlying the role of p53 in cancer cell survival. Copyright 2000 Harcourt Publishers Ltd.
Insights
The p53 tumor suppressor gene is crucial in cancer. Novel strategies aim to either inhibit p53 in normal cells to reduce toxicity or activate p53 in cancer cells to induce apoptosis, improving cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The p53 tumor suppressor gene is frequently mutated in human cancers.
- p53 plays a critical role in regulating cell cycle arrest and apoptosis.
- p53's function is significant in cancer therapy outcomes, particularly in regulating cell death.
Purpose of the Study:
- To explore novel therapeutic strategies targeting the p53 tumor suppressor gene.
- To investigate methods for improving cancer treatment by modulating p53 activity.
- To understand the role of p53 in cancer cell survival and therapy response.
Main Methods:
- Review of animal models and human clinical data regarding p53's prognostic significance.
- Analysis of two distinct therapeutic strategies involving p53 modulation.
- Examination of a peptide-based approach to activate wild-type and mutant p53.
Main Results:
- Two opposing strategies for exploiting p53's function in cancer therapy have been proposed.
- One strategy focuses on inhibiting p53 in normal cells to mitigate treatment-related toxicity.
- Another strategy uses a p53-derived peptide to selectively induce apoptosis in cancer cells.
Conclusions:
- Novel approaches targeting p53 offer potential for enhanced cancer treatment.
- Modulating p53 activity, either inhibition or activation, shows promise in cancer therapy.
- These strategies may elucidate mechanisms of p53 in cancer cell survival and death.